UNS, page-12

There are better financial ratios to scare the bejesus out of Unilife investors than price to book ratios. I think its been explained before that PB ratios is a little bit outdated especially with tech companies whose IP is not captured on the balance sheet. For instance, its estimated that a single Wearable Injector contract could have an NPV of a few hundred million dollars. For a single contract. You wont see this potential captured on Unilife's balance sheet.

Microsoft has a PB of 4. Google thereabouts. Etc.